

1 **Abstract**

2 **Objectives**

3 Endurance exercise is known to cause a rise in serum creatinine. It is not known to what extent
4 this rise reflects renal stress and a potential acute kidney injury (AKI). Increases in Insulin Like
5 Growth Factor Binding Protein 7 (IGFBP7) and Tissue Inhibitor of Metalloproteinases-2 (TIMP-
6 2), urinary biomarkers of cell cycle arrest and renal stress, are associated with the
7 development of AKI.

8

9 **Design**

10 Repeated measures study

11

12 **Methods**

13 Runners were recruited at the 2019 Brighton Marathon (UK) and provided urine and blood
14 samples at baseline, immediately post-race and 24hrs post-race. Serum creatinine, urinary
15 creatinine and urinary IGFBP7 and TIMP-2 were analysed from the samples.

16

17 **Results**

18 Seventy nine participants (23 females, 56 males), aged 43 ± 10 yrs (mean \pm SD), finish time
19 243 ± 40 mins were included for analysis. Serum creatinine increased over the race by $40 \pm$
20 26% ($p < 0.001$), TIMP-2 increased by $555 \pm 697\%$ ($p < 0.001$) and IGFBP7 increased by 1094
21 $\pm 1491\%$ ($p < 0.001$) over the race. A subset of twenty-two participants supplied samples 24
22 hours post-race, reporting values similar to baseline at for all variables by this time. Significant
23 increases ($p < 0.01$) were seen in markers when corrected for urinary creatinine.

24

25 **Conclusions**

26 This study is the first to report large rises in IGFBP7 and TIMP-2 following marathon running.
27 This suggests that rises in creatinine are not fully explained by changes in production and
28 clearance and may reflect a state of kidney stress, or injury.

29

30 **Key words:**

31 Acute kidney injury, biomarker, endurance, running, IGFBP7, TIMP-2

1 **Introduction**

2 An acute rise in serum creatinine is the most widely used clinical measure of acute kidney
3 injury (AKI), a diagnosis associated with significant short and long-term adverse outcomes in
4 acute hospital settings ¹. Increased creatinine concentrations have also been reported in
5 healthy and collapsed endurance events participants ². It has therefore been suggested that
6 endurance running has the potential to impair kidney function and even cause AKI or AKD
7 (acute kidney disease), the long-term sequelae of which may result in the development of
8 chronic kidney disease (CKD) as seen in clinical practice ^{3,4}.

9

10 Measuring changes in serum creatinine concentration in the context of exercise, as in acute
11 care settings, is an imperfect measure of acute kidney function, given the multiple other
12 factors that may elevate serum creatinine ⁵. Exercise associated factors include impaired
13 clearance due to reduced kidney blood flow secondary to intravascular volume depletion ⁶
14 and increased release as a consequence of muscle breakdown ⁷, processes that are
15 augmented by exertional heat stroke ⁸ and exercise induced renal artery vasoconstriction ⁹.
16 These conditions are transient and resolve following cessation of exercise, reflected in a
17 rapid reduction in creatinine concentration in healthy and collapsed endurance events
18 participants ¹⁰. Although transient AKI is observed clinically, it is relatively rare in
19 pathological AKI. Given these observations, it is likely that the rise in creatinine during
20 endurance exercise is multifactorial. It remains to be established to what extent a creatinine
21 rise is physiological or indicative of impaired kidney function, stress, or even acute tubular
22 injury.

23

24 Given serum creatinine is an imperfect “*gold standard*” of kidney function, clinical AKI studies
25 have identified multiple alternative biomarkers of AKI ¹¹. In an exercise setting, the most
26 frequently studied are neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury
27 molecule- 1 (KIM-1) ¹². These biomarkers are not exclusively produced by the kidney at times
28 of acute inflammation and tissue ischaemia,¹³ and may therefore be imperfect measures of
29 kidney stress during exercise. Insulin Like Growth Factor Binding Protein 7 (IGFBP7) and
30 Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) are two proteins involved in G₁ cell cycle
31 arrest. The product of urinary IGFBP7 and TIMP-2 ([TIMP-2] × [IGFBP7]) has been identified
32 as the superior AKI prediction biomarker in critically ill patients in a study of 340 biomarkers,¹³
33 and is FDA approved and commercially available as the NephroCheck® assay. Cell cycle
34 arrest biomarkers are also of interest given sustained cell cycle arrest has been shown to lead
35 to renal fibrosis and development of CKD ^{14,15}.

36

1 To further understand the significance of exercise associated creatinine rise and whether it
2 reflects kidney stress and injury, this study investigated changes in urinary IGFBP7 and TIMP-
3 2 associated with marathon running in participants without evidence of kidney disease.

4 **Method**

5
6 Ninety-one runners (28 females, 63 males), aged 41 ± 10 yrs (mean \pm SD), body mass
7 71.1 ± 11.5 kg, height 174.9 ± 10.0 cm, were recruited at the Brighton Marathon, 14th April 2019.
8 The study was advertised by email and social media to those who had entered and runners
9 then volunteered to take part in the study. Participants provided written informed consent and
10 institutional ethical approval was issued the University of Brighton Life Science Research
11 Ethics Committee (0918). Seventy of the participants had previously completed a marathon.
12 The average number of previous marathons was 5 ± 7 (range 0 to 39). Participants self-
13 reported 3-month training history prior to the marathon involved 43 ± 17 km per week (range 15
14 to 72 km per week).

15
16 Within 48 hours of the marathon, participants were invited to give resting venous blood and
17 urine samples and complete a training diary. Immediately after the marathon, participants were
18 escorted to the medical tent, for venous blood and urine samples. Weather conditions over
19 the day of the marathon were 12-16°C, with 40-50% relative humidity.

20
21 Participants were asked to provide mid-stream urine sample both before and after the
22 marathon. Urine was collected by participants in 30ml Universal Specimen Containers and
23 was then decanted by research staff into 11ml vacuum containers (Vacutainer System, BD,
24 New Jersey, USA). These containers were then placed into freezer containers cooled by liquid
25 nitrogen before being transported to the laboratory.

26
27 Urine analysis was conducted using the NephroCheck® test (Astute Medical Inc, San Diego,
28 USA) and VITROS analysers (Ortho Clinical Diagnostics, Raritan, USA). Urine from each
29 sample was decanted into an individual NephroCheck® cartridge. These were then inserted
30 into the Astute140 analysis device which provided measures of IGFBP7 and TIMP-2. This also
31 provided the NephroCheck® AKIRisk® score calculated as the product of the 2 values ($[\text{TIMP-}$
32 $2] \cdot [\text{IGFBP7}]$) divided by 1000 to produce a single numerical test result with the units of $(\text{ng} \cdot \text{mL}^{-1})^2 \cdot 1000^{-1}$ (the units for all AKIRisk® results and values in this paper)^{16,17}. Urinary Creatinine
34 was measured using VITROS analysers. Urine was refrigerated until analysis and then
35 inserted into the analyser, undiluted, using a CREA VITROS MicroSlide (Ortho Clinical
36 Diagnostics, Raritan, USA).

1 Urine specific gravity and urine proteinuria was assessed using a urinalysis reagent strip
2 (Multistix™ 10 SG, Siemens Healthcare GmbH., Erlangen, Germany). Proteinuria was
3 defined, using a categorical scale: negative (0 g.L⁻¹), trace (0.15 g.L⁻¹), + (0.3 g.L⁻¹), ++ (1 g.L⁻¹)
4 ¹), +++ (3 g.L⁻¹) and specific gravity using an interval scale: 1.000 to 1.030 in 0.005 increments.

5
6 Venous blood was collected by experienced phlebotomists using the Vacutainer System (BD,
7 New Jersey, USA) in a serum separating tube. These samples were also frozen and then
8 serum creatinine concentration was measured using the Abcam fluorometric assay (Abcam
9 Ltd, Cambridge, UK).

10
11 Data was assessed for normality and sphericity and adjusted where necessary using the
12 Huynh-Feldt method. Paired samples t-tests were used to compare pre and post-race values
13 of the 79 runner pre to post-race. One way ANOVA was used to compare across the three
14 time points for the sub-set of 22 runners tested 24hr post-race. Both Pearson's and Spearman
15 correlation were used where appropriate to determine relationship between urine biomarkers
16 and race variables. All statistical tests were completed using SPSS Statistics 26 (IBM, New
17 York) and figures using DataGraph (4.7.1, Visual Data Tools). Significance was accepted at
18 $p < 0.05$. Values are reported as mean \pm SD unless otherwise indicated.

21 **Results**

22 Eighty participants completed the marathon, 11 did not finish, and 1 finished but did not
23 provide a post-race sample. Therefore 79 participants (23 females, 56 males, aged 43 ± 10 yrs,
24 finish time 243 ± 40 mins) were included for analysis. Twenty-two of the participants, all of
25 whom had finished and provided a post-race sample, returned for testing 24hrs post marathon.
26 Average heart rate for the marathon was 153 ± 32 bts.min⁻¹. Five participants reported minor
27 medical issues over the race (n): muscle cramps (3), asthma exacerbation (1), gastrointestinal
28 disturbance (1). Consumption of medications 48 hours pre-race included (n): paracetamol (1),
29 ibuprofen (2), aspirin (2). Consumption of nutritional supplements 48 hours pre or during race
30 included (n): carbohydrate gels (10), protein powder supplements (6). Consumption of
31 medications 48 hours post-race included (n): paracetamol (9), ibuprofen (2), aspirin (2).

32
33 Table 1 and Figure 1 detail serum creatinine and urinary measures at the three sample points.
34 From the 79 runners, serum creatinine increased over the race by $40 \pm 26\%$ ($p < 0.001$), TIMP-
35 2 increased by $555 \pm 697\%$ ($p < 0.001$) and IGFBP7 increased by $1094 \pm 1491\%$ ($p < 0.001$) from
36 baseline to post race. The subset of 22 runners also demonstrated the same significant
37 increase ($p < 0.01$) pre to post race, with biomarkers returning to near baseline at 24 hours

1 post-race. A similar trend but lower magnitude rise was seen in biomarker values when
2 corrected for urinary creatinine concentration.

3
4 Forty three participants (54%) had a creatinine rise $>26.5 \mu\text{mol/l}$ (AKI stage 1 criteria) and 1
5 had a rise over 2.0 times from their baseline level (AKI stage 2 criteria)¹⁸ (range -4 to 107
6 $\mu\text{mol.L}^{-1}$). Sixty nine (86%) participants had a post-race [TIMP-2]•[IGFBP7] value $>0.3 (\text{ng.mL}^{-1})^2.1000^{-1}$ (range 0.08 to 40.14), the value indicative of high risk of imminent AKI in critically ill
7 patients¹⁹. Thirty three (41%) of participants had a post race [TIMP-2]•[IGFBP7] value >2.0
8 $(\text{ng.mL}^{-1})^2.1000^{-1}$, a threshold associated with a 95% specificity for predicting AKI
9 development. Mean serum creatinine and [TIMP-2]•[IGFBP7] returned to baseline at 24 hours
10 post race ($p<0.005$). All participants' creatinine, TIMP-2 or IGFBP7 levels at 24 hours were
11 lower compared to the immediate post-race value.

12
13
14 There was no association between measures of creatinine, TIMP-2 or IGFBP7 and
15 participants' demographics, self-reported training volume, number of previous marathons,
16 marathon finish time or average heart rate ($r<0.25, p>0.05$). TIMP-2 and IGFBP7 values were
17 correlated ($p<0.01$) at all corresponding time points (pre-race $r=0.65$, post-race $r=0.91$). Figure
18 2 demonstrates the association ($p<0.01$) between pre to post race change in creatinine and
19 [TIMP-2]•[IGFBP] ($r=0.43$), with no significant difference between TIMP-2 ($r=0.43$) and
20 IGFBP7 ($r=0.48$). A trend that was maintained when correction for urinary creatinine was
21 applied TIMP-2 ($r=0.45$), IGFBP7 ($r=0.64$) and [TIMP-2]•[IGFBP7] ($r=0.63$). There was no
22 predictive relationship between pre and post-race [TIMP-2]•[IGFBP7].

23
24 Markers of urinary concentration (urinary creatinine and specific gravity) were associated with
25 TIMP-2 and IGFBP7 at baseline and post-race ($p<0.01$). Baseline [TIMP-2]•[IGFBP7] was
26 strongly associated with urinary creatinine ($r=0.72$), whilst moderate associations were
27 present between post-race [TIMP-2]•[IGFBP7] and urinary creatinine ($r=0.65$). There was no
28 association between serum creatinine and urinary creatinine (Figure 2).

29 30 **Discussion**

31 This study is the first to examine the effect of marathon running on TIMP-2 and IGFBP, two
32 urinary biomarkers of cell cycle arrest that strongly predict development of AKI in clinical
33 populations. TIMP-2 and IGFBP7 increased following marathon running and this rise was
34 moderately correlated with the rise in serum creatinine. Adjusting the TIMP-2 and IGFBP7
35 values for urinary creatinine, reduced the magnitude of the increase but maintained the
36 association with serum creatinine rise.

1 TIMP-2 and IGFBP7 are proteins involved in the initiation of G₁ cell cycle arrest, a process
2 that is a response to kidney epithelium stress and prevents mitosis occurring in an
3 environment that is at higher risk of DNA damage ¹³. They are exclusively produced within
4 the kidney, therefore the increase levels relate to processes within the kidney alone. The rise
5 in TIMP-2 and IGFBP-7 following marathon running supports the hypothesis that the serum
6 creatinine rise that occurs with marathon running is, at least in part, related to kidney stress
7 and potential damage and not only due to increased creatinine production or decreased
8 clearance ². This may reflect the effects of systemic inflammation ²⁰ or reduced renal blood
9 flow ²¹ that are associated with exercise.

10
11 The return to baseline of creatinine, TIMP-2 and IGFBP7 at 24 hours following race completion
12 is consistent with previous studies of exercise and kidney function markers ²². The rapid
13 normalisation of creatinine, TIMP-2 and IGFBP7 for most participants can be attributed to the
14 cessation of exercise and return to baseline physiology. However, a significant number of
15 participants who returned at 24 hours had one or more persistently elevated markers, with an
16 increased spread of results when compared to the baseline measures. The cause of delayed
17 normalisation of creatinine is likely multifactorial, although studies with follow up beyond 24
18 hours post cessation of exercise have demonstrated a return to baseline in all participants
19 ^{23,24}. The significance of persistent evidence of renal tubular cell cycle arrest requires further
20 investigation. It is reassuring that in all cases the levels were falling when compared with the
21 immediate post-run values, however it should be considered that runners with persistently
22 elevated values may be more susceptible to an exercise-mediated kidney insult.

23
24 Few studies have explored the relationship between creatinine and urinary biomarkers, with
25 one marathon study reporting poor correlation between creatinine and uNGAL ²⁵. Elevations
26 in TIMP-2 and IGFBP7 were moderately correlated with creatinine rise. This study supports
27 the consensus that measuring the serum creatinine alone to detect kidney stress during
28 exercise is inadequate. Participants with disproportionately small and large changes in serum
29 creatinine relative to the cell cycle arrest biomarkers were identified in this study. A raised
30 creatinine following exercise may represent increased solute load without significant kidney
31 injury, whilst creatinine clearance could be maintained due to increased tubular flow despite
32 the presence of some degree of kidney stress. No observational studies exist regarding the
33 effects of chronic endurance exercise participation and kidney function, although associations
34 between both recurrent AKI and cell cycle arrest and CKD have been suggested ^{14,15}.

35
36 The increase in TIMP-2 and IGFBP7 was closely correlated, however the magnitude of
37 increase was greater in IGFBP7. This variation in response is consistent with the only prior

1 study examining TIMP-2 and IGFBP7 during exercise that observed an increase in IGFBP7
2 but not TIMP-2 during a 2 hour walking bout in warm and humid conditions ²⁶. This variation
3 may reflect the site of kidney stress given IGFBP7 is expressed in both proximal and distal
4 tubular epithelial cells but secreted predominantly in the proximal tubule cells, whereas TIMP-
5 2 is expressed and secreted primarily in distal tubule cells ²⁷.

6
7 Unsurprisingly, correction for urinary creatinine concentration in this study reduced the
8 magnitude of urinary biomarker rise but maintained the associations with serum creatinine.
9 The validity of correcting urinary biomarkers to urinary creatinine to account for increased
10 urine osmolality during exercise is not known given the dynamic fluctuations in creatinine
11 production and glomerular filtration that occur. Variation in urine production during exercise
12 influences biomarker values, with oliguria and increased urine osmolality causing an increase
13 in urinary biomarker concentration. A finding observed in this study with a moderate
14 association between rises in both IGFBP7 and TIMP-2 and specific gravity.

15
16 The optimal dose of physical activity for maximising health benefits is unknown. However,
17 there is evidence that more extreme exercise could be harmful ^{28,29}. The Copenhagen City
18 Heart Study findings of a U-shaped association between all-cause mortality and dose of
19 jogging warrant further investigation of biomarkers of organ stress and injury and endurance
20 exercise ²⁹. Although the benefits of exercise in patients with CKD are well established, there
21 have been no studies on endurance event participation and long-term kidney function. As
22 sports and exercise medicine increasingly explores personalised response to physical activity,
23 the longitudinal use of a panel of biomarkers, including those of kidney function, should be of
24 significant interest, particular for individuals with known susceptibility to specific organ
25 dysfunction. This study indicates that marathon running has the potential to induce cell cycle
26 arrest, a finding of significant relevance given the emerging evidence that recurrent cell cycle
27 arrest is associated with increased DNA damage, a potential mechanism for the development
28 of fibrosis and CKD ¹⁵.

29
30 Limitations of this study include a relatively low number of participants sampled at 24 hours
31 post-race, however the distribution of results replicated previous work demonstrating a return
32 toward baseline levels in the majority. Longer-term follow-up is desirable, including the
33 investigation of the effects of repeated participation in endurance eventing. The participant
34 retention was comparable to similar studies utilising a large city marathon as the subject of
35 pre and post physiological variable analysis ³⁰.

36
37

1 **Conclusion**

2 Increases in TIMP-2 and IGFBP7 kidney cell cycle arrest biomarkers following a marathon
3 suggest that rises in serum creatinine previously associated with endurance exercise are, at
4 least in part, related to kidney stress. The moderate association between these cell cycle
5 arrest biomarkers and serum creatinine indicates that further consideration should be given to
6 the development of tools for assessing kidney stress, function, and damage in the context of
7 exercise.

8

9 **Practical implications**

- 10
- 11 • The magnitude of serum creatinine change following exercise does not necessarily
12 correlate to the degree of kidney stress and potential injury incurred.
 - 13 • Marathon running is associated with inducing cell cycle arrest in both proximal and
14 distal tubular cells of the kidney.
 - 15 • Cell cycle arrest is a process associated with DNA damage and the development of
16 renal fibrosis and CKD, further study of the long-term consequences of exercise
induced kidney stress is warranted.

17

18

19

20

1 **References**

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

- 1 Ronco C, Bellomo R, Kellum JA. Acute kidney injury. *Lancet* 2019; 394(10212):1949–1964. Doi: 10.1016/s0140-6736(19)32563-2.
- 2 Hodgson L, Walter E, Venn R, et al. Acute kidney injury associated with endurance events—is it a cause for concern? A systematic review. *BMJ Open Sport Exerc Med* 2017; 3(1):e000093. Doi: 10.1136/bmjsem-2015-000093.
- 3 Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. *N Engl J Med* 2014; 371(1):58–66. Doi: 10.1056/NEJMRA1214243.
- 4 Sawhney S, Marks A, Fluck N, et al. Post-discharge kidney function is associated with subsequent ten-year renal progression risk among survivors of acute kidney injury. *Kidney Int* 2017; 92(2):440. Doi: 10.1016/J.KINT.2017.02.019.
- 5 Waikar SS, Betensky RA, Emerson SC, et al. Imperfect Gold Standards for Kidney Injury Biomarker Evaluation. *J Am Soc Nephrol* 2011; 23(1):13–21. Doi: 10.1681/asn.2010111124.
- 6 Mansour SG, Verma G, Pata RW, et al. Kidney Injury and Repair Biomarkers in Marathon Runners. *Am J Kidney Dis* 2017; 70(2):252–261. Doi: 10.1053/j.ajkd.2017.01.045.
- 7 Fragala MS, Bi C, Chaump M, et al. Associations of aerobic and strength exercise with clinical laboratory test values. *PLoS One* 2017; 12(10):e0180840. Doi: 10.1371/journal.pone.0180840.
- 8 Walter E, Venn R, Stevenson T. Exertional Heat Stroke – The Athlete’s Nemesis. *J Intensive Care Soc* 2012; 13(4):304–308. Doi: 10.1177/175114371201300408.
- 9 Middlekauff HR, Nitzsche EU, Nguyen AH, et al. Modulation of renal cortical blood flow during static exercise in humans. *Circ Res* 1997; 80(1):62–68. Doi: 10.1161/01.RES.80.1.62.
- 10 Fitzpatrick D, Walter E, Leckie T, et al. Association between collapse and serum creatinine and electrolyte concentrations in marathon runners. *Eur J Emerg Med* 2020:1–9. Doi: 10.1097/MEJ.0000000000000739.
- 11 Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. *JAMA Netw Open* 2020; 3(10):e2019209. Doi: 10.1001/JAMANETWORKOPEN.2020.19209.
- 12 Juett LA, James LJ, Mears SA. Effects of Exercise on Acute Kidney Injury Biomarkers and the Potential Influence of Fluid Intake. *Ann Nutr Metab* 2021; 76 Suppl 1. Doi: 10.1159/000515022.

- 1 13 Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest
2 biomarkers in human acute kidney injury. *Crit Care* 2013; 17(1):R25. Doi:
3 10.1186/cc12503.
- 4 14 Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M
5 mediates kidney fibrosis after injury. *Nat Med* 2010; 16(5):535–543. Doi:
6 10.1038/nm.2144.
- 7 15 Canaud G, Bonventre J V. Cell cycle arrest and the evolution of chronic kidney
8 disease from acute kidney injury. *Nephrol Dial Transplant* 2015; 30(4):575–583. Doi:
9 10.1093/NDT/GFU230.
- 10 16 Nalesso F, Cattarin L, Gobbi L, et al. Evaluating nephrocheck as a predictive tool for
11 acute kidney injury. *Int J Nephrol Renovasc Dis* 2020:85–96. Doi:
12 10.2147/IJNRD.S198222.
- 13 17 Fan W, Ankawi G, Zhang J, et al. Current understanding and future directions in the
14 application of TIMP-2 and IGFBP7 in AKI clinical practice. *Clin Chem Lab Med*
15 2019:567–576. Doi: 10.1515/cclm-2018-0776.
- 16 18 Kellum JA, Lameire N, Aspelin P, et al. Diagnosis, evaluation, and management of
17 acute kidney injury: A KDIGO summary (Part 1). *Crit Care* 2013; 17(1). Doi:
18 10.1186/cc11454.
- 19 19 Bihorac A, Chawla LS, Shaw AD, et al. Validation of cell-cycle arrest biomarkers for
20 acute kidney injury using clinical adjudication. *Am J Respir Crit Care Med* 2014;
21 189(8):932–939. Doi: 10.1164/rccm.201401-0077OC.
- 22 20 Barros ES, Nascimento DC, Prestes J, et al. Acute and Chronic Effects of Endurance
23 Running on Inflammatory Markers: A Systematic Review. *Front Physiol* 2017;
24 8(OCT):779. Doi: 10.3389/FPHYS.2017.00779.
- 25 21 Kawakami S, Yasuno T, Matsuda T, et al. Association between exercise intensity and
26 renal blood flow evaluated using ultrasound echo. *Clin Exp Nephrol* 2018;
27 22(5):1061–1068. Doi: 10.1007/S10157-018-1559-1.
- 28 22 Wołyniec W, Ratkowski W, Renke J, et al. Changes in Novel AKI Biomarkers After
29 Exercise. A Systematic Review. *Int J Mol Sci* 2020:1–20. Doi: 10.3390/ijms21165673.
- 30 23 Page AJ, Reid SA, Speedy DB, et al. Exercise-associated hyponatremia, renal
31 function, and nonsteroidal antiinflammatory drug use in an ultraendurance mountain
32 run. *Clin J Sport Med* 2007; 17(1):43–48. Doi: 10.1097/JSM.0b013e31802b5be9.
- 33 24 Hewing B, Schattke S, Spethmann S, et al. Cardiac and renal function in a large
34 cohort of amateur marathon runners. *Cardiovasc Ultrasound* 2015; 13(1):13. Doi:
35 10.1186/s12947-015-0007-6.
- 36 25 Lippi G, Sanchis-Gomar F, Salvagno GL, et al. Variation of serum and urinary
37 neutrophil gelatinase associated lipocalin (NGAL) after Strenuous physical exercise.

- 1 *Clin Chem Lab Med* 2012; 50(9):1585–1589. Doi: 10.1515/cclm-2011-0954.
- 2 26 Chapman CL, Johnson BD, Vargas NT, et al. Both hyperthermia and dehydration
3 during physical work in the heat contribute to the risk of acute kidney injury. *J Appl*
4 *Physiol* 2020; 128(4):715–728. Doi: 10.1152/jappphysiol.00787.2019.
- 5 27 Emllet DR, Pastor-Soler N, Marciszyn A, et al. Insulin-like growth factor binding protein
6 7 and tissue inhibitor of metalloproteinases-2: Differential expression and secretion in
7 human kidney tubule cells. *Am J Physiol - Ren Physiol* 2017; 312(2):F284–F296. Doi:
8 10.1152/ajprenal.00271.2016.
- 9 28 Paffenbarger RS, Hyde R, Wing AL, et al. Physical activity, all-cause mortality, and
10 longevity of college alumni. *N Engl J Med* 1986; 314(10):605–613. Doi:
11 10.1056/NEJM198603063141003.
- 12 29 Schnohr P, O’Keefe JH, Marott JL, et al. Dose of jogging and long-term mortality: the
13 Copenhagen City Heart Study. *J Am Coll Cardiol* 2015; 65(5):411–419. Doi:
14 10.1016/J.JACC.2014.11.023.
- 15 30 Whatmough S, Mears S, Kipps C. Serum sodium changes in marathon participants
16 who use NSAIDs. *BMJ Open Sport Exerc Med* 2018; 4(1). Doi: 10.1136/BMJSEM-
17 2018-000364.
- 18
- 19
- 20
- 21

1 **List of Tables**

2

3 **Table 1:** Serum and urinary biomaker values values pre, immediately post and 24hrs post
 4 marathon. Data presented as mean (\pm SD). *denotes significant difference from pre-race
 5 values.

6

7

	Pre-race	Post-race	24hr post-race
<i>Pre and post-race dataset</i>	91	79	-
<i>Pre, post and 24 hour post-race subset</i>	21	21	21
Serum creatinine ($\mu\text{mol.L}^{-1}$)	80.1 (11.1) 80.4 (12.8)	112.2 (22.6)* 118.8 (25.6)*	- 85.5 (15.9)
TIMP-2 (ng.dL^{-1})	2.4 (1.2) 2.3 (0.9)	12.4 (9.1)* 14.1 (10.1)*	- 3.2 (2.2)
TIMP-2/urinary creatinine (ng.mg^{-1})	1.8 (1.2) 4.9 (3.3)	6.4 (3.16)* 7.7 (4.6)*	- 4.0 (3.63)
IGFBP-7 (ng.dL^{-1})	32.3 (25.5) 29.0 (22.7)	236.6 (218.9)* 255.9 (203.7)*	- 36.5 (35.6)
IGFBP-7/urinary creatinine (ng.mg^{-1})	18.6 (7.7) 51.7 (21.5)	114.5 (74.8)* 49.1 (36.1)*	- 36.5 (20.5)
[TIMP-2]•[IGFBP] (ng.dL^{-1})²/1000	0.10 (0.12) 0.08 (0.09)	4.74 (8.26)* 5.38 (8.23)*	- 0.18 (0.26)
[TIMP-2]•[IGFBP]/urinary creatinine ((ng.dL)²•100⁻¹/mg.dL⁻¹)	2.8 (2.8) 0.45 (0.37)	1.80 (2.27)* 9.2 (11.8)*	- 1.9 (2.7)
Urinary creatinine (mg.dL^{-1})	69.6 (50.7) 60.4 (51.6)	207.7 (124.9)* 212.2 (139.3)*	- 113.9 (80.8)

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1 **List of Figures**

2

3 **Figure 1:** Serum creatinine, TIMP-2 and IGFBP7 pre, post and 24 hours post marathon. Red
4 lines indicate mean values for runner tested pre and post-race. Black lines indicate means for
5 subset (n=21) completing pre, post and 24 hours post-race tests *Denotes significant
6 difference from other time points.

7

8 **Figure 2:** Pre to post race change in serum creatinine and [TIMP-2]•[IGFBP7]. Coloured areas
9 indicate AKI Risk levels (Green < 0.3, Yellow 0.3 - 2, Red > 2). Dashed black line indicates a
10 serum creatinine increase of >26.5 $\mu\text{mol.L}^{-1}$. Colour of the markers indicates scale of change
11 pre to post-race urine creatinine (Green <68 (<IQR1), Blue 69-179 (IQR 1-3), Red >179 mg.dL⁻¹
12 (>IQR 4)) with no association between serum creatinine and urine creatinine change
13 ($r=0.09$).

14

15

16

17

18